Botox Competitor ‘Dysport’ Now FDA Approved

A new Botox competitor from Ipsen and Medicis Pharmaceutical has received FDA approval for treating wrinkles and dystonia. Plastic surgeons and dermatologists may have the drug available for cosmetic use in just 30 – 60 days.

Rather than rebranding the drug ‘Reloxin’ as planned, Medicis decided to retain its original European name, Dysport

The April 30th announcement coincided with a 3 percent drop in Allergan’s (maker of Botox) shares, and a 14 percent increase of Medicis shares. Analysts and industry professionals expect Dysport to carry a slightly lower price tag than Botox, and say it could capture as much as 30 percent of the current market.

Botox and Dysport both perform the same basic function – neuromuscular blocking to relax and prevent wrinkles. Dysport however, is said to be more diluted than Botox and thus more cost effective for providers. The recent FDA approval of dysport also came with a unique warning label describing the risks associated with the botulinum toxin.

For more information on wrinkle treatments in Seattle, see our homepage.

‘Dysport’ – A Botox Alternative Could Become Available Later This Year

dysport1An article published in Archives of Facial Plastic Surgery includes the results of a clinical study for the new wrinkle relaxer, Dysport. The long-term (13 months) safety of Dysport for repeated use in moderate to severe forehead wrinkles was evaluated by doctors.

The product manufacturer, Medicis Pharmaceutical expects to receive FDA approval for the drug later this year. This could bring the first real Botox competitor to the cosmetic surgery market of the U.S. – a market which allowed Allergan Inc. to net $1.3 billion in revenue last year with Botox.

A participating Los Angeles dermatologist commented to Bloomberg news about the study, saying the side effects are the same as Botox” and “many of our patients liked it even better.

Dysport and Botox are both composed of a special ‘botulinum toxin’ that has been shown to relax the muscles that cause wrinkles in the face. Dysport has been sold outside the US for over 15 years, but Botox has still managed to claim over 80 percent of the worldwide market for the neurotoxin. One market analyst speculates that “[the new drug] may be priced 15 percent lower than Botox” which could allow it to take a significant share of the market.

Free Consultation
close slider

Contact Us

Best time to contact?
MorningAfternoonEvening
Sign up for email specials?
YesNo